Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24899414 | 0.89 | MME (0.35) | MMEALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL26857865 | 0.88 | MME (0.34) | MMEALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL24915216 | 0.88 | MME (0.34) | MMEALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL26857875 | 0.85 | MME (0.33) | MME | |
| SCHEMBL26858396 | 0.78 | ALDH1A1 (0.33) | MMEALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL24915323 | 0.77 | ACE (0.33) | ACE | |
| SCHEMBL23901226 | 0.74 | ALDH1A1 (0.44) | MMEALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL13330257 | 0.74 | MME (0.41) | MMEALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL16790758 | 0.74 | APEX1 (0.39) | ALDH1A1TDP1CES2 | |
| SCHEMBL25608399 | 0.74 | ALDH1A1 (0.39) | MMEALDH1A1LMNAMAPTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374073-A1 | DIMERIC MILLA IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230365627-A1 | MACROCYCLIC PEPTIDE BORONATE IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365627-A1 | MACROCYCLIC PEPTIDE BORONATE IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MME 2174/4885ALDH1A1 4129/4885LMNA 4635/4885 |
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MME 2503/4885ALDH1A1 3750/4885LMNA 4726/4885 |
| US-20230374073-A1 | DIMERIC MILLA IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MME 989/4885ALDH1A1 3255/4885LMNA 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.